WHO Raises Alert Over Critical Scarcity of Obesity Jabs
Under one in 10 people eligible to benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it releases its initial recommendations on the therapies.
With over a billion individuals worldwide currently obese, it is advocating for more widespread and fairer availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our new guidelines acknowledges that obesity is a chronic disease that can be addressed with holistic and lifelong care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are key hurdles to universal availability to the injections that can help people shift considerable weight, explains the body.
Weight-Loss Drug Supply Crisis
Despite the present most favorable case, the production of these medications might only reach around 100 million people – less than 10% of eligible patients, as stated by the health organization.
The advice urges countries and companies to increase access, through measures such as licensing agreements.
A patent on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.
How Obesity Drugs Work
GLP-1 drugs imitate a biological compound to delay gastric emptying, curb appetite and increase feelings of fullness so people consume fewer calories.
Individuals commonly begin shedding pounds after several weeks of beginning the once-weekly jabs.
Studies points to users may see weight return after a year of discontinuing the medication, when their normal hunger resume.
Being overweight or obese elevates your chance for contracting health problems, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns people in every country and was responsible for over three and a half million deaths worldwide in 2024, according to the WHO.
